We're honored to announce that Francesca Cottini, MD, has earned the inaugural Mason Fisher Grant. The award, funded by @Pelotonia, supports research of genetic mutations that can lead to cancer. https://t.co/4Zv150jkYG
🥼 Researchers led by Dr. @FrancescaCottin at @OhioStateMed identified non-classical major histocompatibility complex class I molecule HLA-E as a major contributing factor in #immune escape.
👓 Learn more at @LeukemiaJnl | https://t.co/9MAUO5eTmL
#Myeloma Paper of the Day: CREB1 promotes expression of immune checkpoint HLA-E, which binds to natural killer group 2A (NKG2A) inhibitory NK signal signal, leading to immune escape in multiple myeloma: https://t.co/LUOWgxVO2w.
Excite and honored to be a part of AMPATH myeloma workshop in Eldoret, Kenya, to educate and mentor providers, engage with key stakeholders and advocacy groups to make bispecific antibodies available in Western Africa. #AMPATH#MoiUniversity#IUCancerCenter#IUSchoolMedicine
#myeloma Happy to share the last work of our lab on the role of CD56 in predicting response to Dara-IMiDs in patients with myeloma. Thanks to my team, especially AJ Robinette @OSUHematology@OhioStateWIMS@Pelotonia
Excellent @OSUCCC_James Oncogeriatric Grand Rounds today by @MegVoda 10% of skeleton bone is remodeled annually. Fascinated by 🦴 pits and trenches and relationship to #gerionc and senescence. @OSUHematology
OncData had the pleasure of speaking with Dr. Evandro Bezerra (@E_D_Bezerra) of @OSUHematology about his study "Real-World Outcomes of #BrexuCel for R/R B-Cell #ALL. Stay tuned to hear the podcast!
Pub Alert 🚨 @FrancescaCottin and other members from the #MultipleMyeloma Team published “Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma” in @FrontOncology
https://t.co/DsgskelJRK